APYX Q4 2023: Advanced Energy Sales Up 15% as Macro Headwinds Pressure Generator Pipeline
APYX Medical delivered double-digit advanced energy growth, but capital equipment demand remains hampered by persistent macro uncertainty and high interest rates. Handpiece utilization and new product launches offset generator softness, yet management’s 2024 outlook signals a cautious stance with limited near-term rebound expected. Investors should watch for handpiece-driven resilience and the timing of a capital market recovery to unlock the next leg of growth.
Summary
- Handpiece Utilization Drives Offsetting Growth: Strong U.S. handpiece demand and new product launches sustained segment momentum despite generator softness.
- Capital Equipment Overhang Persists: Management signals no near-term relief from macro-driven delays in generator purchases.
- 2024 Guidance Anchored in Caution: Revenue outlook assumes continued headwinds, with handpieces expected to anchor stability as capital demand lags.
Business Overview
APYX Medical is a medical technology company specializing in advanced energy-based surgical solutions for the cosmetic surgery market. Its core revenue streams are split between Advanced Energy (primarily Renuvion-branded generators and handpieces for tissue coagulation and body contouring) and OEM (original equipment manufacturing for third-party medical device companies).
Performance Analysis
APYX posted solid top-line growth, with total revenue up 16% year-over-year in Q4, driven by a 15% increase in advanced energy sales and a 22% jump in OEM. The advanced energy segment, which makes up the majority of revenue, saw robust handpiece demand—especially in the U.S., where handpiece sales surged over 35% and generator sales to existing customers benefited from the APEX One upgrade program.
However, the capital equipment environment remained a drag. New generator sales to U.S. customers were down, reflecting ongoing macroeconomic uncertainty and high interest rates. International generator sales grew sharply, but this was offset by a decline in international handpiece sales. Gross margin compressed to 60.9% from 65.3%, reflecting product mix shifts, lower pricing, and higher input and shipping costs. Cash flow improved year-over-year, aided by working capital discipline, and the company ended the year with $44 million in cash following a new $45 million credit facility.
- Handpiece Utilization Resilience: U.S. handpiece sales growth outpaced expectations, mitigating generator softness.
- Product Mix Pressures Margin: Lower average selling prices, higher costs, and inventory reserves pressured gross margin.
- OEM Volatility: OEM revenue rose, but segment margin headwinds and normalization are expected in 2024.
Despite capital equipment headwinds, APYX maintained double-digit growth for the year and made progress on cost containment, but profitability remains elusive with net loss and adjusted EBITDA loss both widening year-over-year.
Executive Commentary
"The capital equipment environment in the fourth quarter proved to be more challenging than we had anticipated with more prospective customers delaying investments given continued concerns related to broader macroeconomic uncertainty as well as the financing environment."
Charlie Goodwin, President and Chief Executive Officer
"Gross margins in Q4 were down to 60.9%. A little more than half of that was related to inventory cleanup at year end for some slow-moving inventory with additional reserves. And the remainder was associated primarily with product mix in our A segment, both product and customer mix."
Matt Hill, Chief Financial Officer
Strategic Positioning
1. Handpiece-Driven Utilization Anchors Revenue
Handpiece sales, the consumable component of the APYX platform, have become the primary growth engine as generator sales slow. The launch of the Renuvion Micro Handpiece, compatible only with the APEX One generator, is designed to drive both incremental utilization and encourage generator upgrades among existing users. Management expects handpiece demand to remain robust, particularly as body contouring procedures and patient awareness increase.
2. Capital Equipment Sales Remain Constrained
Generator sales to new customers continue to underperform, with macro uncertainty and high rates limiting capital purchases. While APYX has introduced financing options and targeted upgrade programs, the pipeline remains strong but delayed, with surgeons deferring purchases rather than rejecting the technology. Management does not expect a significant rebound in capital equipment demand in 2024.
3. OEM Segment Faces Margin and Volume Normalization
OEM revenue provided a boost in Q4, but management’s 2024 guide anticipates a pullback. The segment’s gross margin is under pressure from mix and cost inflation, and the full-year impact of a sales leaseback adds further drag. This segment is expected to be less of a growth lever in the near term.
4. Direct-to-Consumer (DTC) and Market Education Initiatives
APYX is investing in DTC campaigns and physician education to raise awareness of Renuvion’s clinical benefits and FDA clearances. These efforts are intended to build demand and support handpiece utilization, especially as social media and new patient cohorts (such as GLP-1 drug users) expand the addressable market.
5. Regulatory and Clinical Evidence as Differentiators
APYX emphasizes its unique FDA 510(k) clearances and a growing body of clinical evidence (over 92 papers), positioning Renuvion as a differentiated solution for body contouring and tissue coagulation. This regulatory and evidence moat is a key strategic asset in conversations with surgeons and in competitive positioning.
Key Considerations
APYX’s Q4 and 2023 results highlight a business in transition, with handpiece utilization and new product launches offsetting capital equipment headwinds. The company’s ability to navigate persistent macro challenges while investing in future growth drivers will be critical to its trajectory.
Key Considerations:
- Handpiece-Driven Growth vs. Generator Lag: Handpiece sales are offsetting generator softness, but sustained growth will require eventual capital market recovery.
- Margin Compression Signals Mix Risk: Gross margin contraction reflects unfavorable product and customer mix and higher input costs.
- OEM Segment Volatility: OEM revenue is expected to normalize downward, with margin headwinds persisting into 2024.
- Cash Position Provides Runway: $44 million in cash and a new credit facility offer flexibility, but ongoing losses require careful resource allocation.
- DTC and Clinical Evidence Build Moat: Investment in patient and physician awareness and clinical validation supports long-term adoption.
Risks
Ongoing macroeconomic uncertainty, high interest rates, and capital spending caution among surgeons continue to limit generator sales visibility. Gross margin pressure from mix and cost inflation could persist if OEM or geographic mix shifts further. Regulatory delays in key international markets (such as Korea and China) remain a potential drag, and ongoing operating losses could pressure cash if growth does not rebound as expected. Management’s guidance is predicated on no major improvement in capital equipment demand and assumes stable handpiece utilization.
Forward Outlook
For Q1 2024, APYX expects:
- Advanced energy revenue to decline approximately 40% sequentially from Q4, reflecting seasonality and ongoing capital equipment headwinds.
For full-year 2024, management guided:
- Total revenue of $49.7 million to $52.9 million, representing a range from a 5% decline to 1% growth.
- Advanced energy revenue of $41.6 million to $44.6 million, down 4% to up 3%.
- OEM revenue of $8.1 million to $8.3 million, down 10% to 7%.
- Gross margin around 61%, with operating expenses and net loss both expected to rise year-over-year.
Management highlighted:
- Handpiece utilization and DTC initiatives as key stabilizers.
- No major rebound in capital equipment expected in 2024, with improvement possible in the back half but not forecasted.
Takeaways
APYX faces a challenging near-term market but is leveraging handpiece utilization, new product launches, and a strong clinical evidence base to sustain momentum. The company’s cash position provides runway, but the timing of a capital equipment recovery is key for upside.
- Handpiece Utilization Remains the Growth Anchor: As generator sales lag, consumable demand and new product introductions are central to revenue stability.
- Margin and OEM Headwinds Require Monitoring: Mix and cost inflation are pressuring profitability, and OEM normalization will limit upside.
- Watch for Capital Equipment Recovery: A turn in macro or financing conditions could unlock pent-up generator pipeline, but management is not forecasting this for 2024.
Conclusion
APYX delivered double-digit advanced energy growth in a tough macro environment, relying on handpiece demand and new product launches to offset generator headwinds. Management’s cautious 2024 outlook reflects persistent capital equipment uncertainty, with handpiece utilization and DTC investment expected to anchor near-term performance.
Industry Read-Through
Cosmetic surgery device markets remain highly sensitive to capital spending cycles, with macro uncertainty and high interest rates delaying equipment purchases across the industry. Consumable-driven models (like handpieces) are proving more resilient, while OEM and capital equipment segments are exposed to mix and pricing volatility. The growing influence of DTC marketing and clinical evidence as adoption drivers is likely to accelerate across medical device categories, especially as new patient cohorts (such as GLP-1 users) expand the addressable market. Competitors should note the importance of regulatory clearances and real-world data in differentiating solutions and driving long-term adoption.